CN113712858A - Preparation and application of antibacterial and anti-inflammatory plant extract composition - Google Patents
Preparation and application of antibacterial and anti-inflammatory plant extract composition Download PDFInfo
- Publication number
- CN113712858A CN113712858A CN202110771103.8A CN202110771103A CN113712858A CN 113712858 A CN113712858 A CN 113712858A CN 202110771103 A CN202110771103 A CN 202110771103A CN 113712858 A CN113712858 A CN 113712858A
- Authority
- CN
- China
- Prior art keywords
- composition
- basil
- mass ratio
- chlorogenic acid
- filtering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 23
- 239000000419 plant extract Substances 0.000 title claims abstract description 23
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 29
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 29
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 29
- 235000010676 Ocimum basilicum Nutrition 0.000 claims abstract description 29
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 29
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 29
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 29
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 29
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 29
- 241001529734 Ocimum Species 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 241000219061 Rheum Species 0.000 claims abstract description 18
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
- 239000000706 filtrate Substances 0.000 claims description 38
- 238000001914 filtration Methods 0.000 claims description 27
- 239000000284 extract Substances 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 19
- 230000003385 bacteriostatic effect Effects 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 13
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 108010059892 Cellulase Proteins 0.000 claims description 11
- 229940106157 cellulase Drugs 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000008395 clarifying agent Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000005520 cutting process Methods 0.000 claims description 7
- 238000001471 micro-filtration Methods 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 230000010355 oscillation Effects 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000012074 organic phase Substances 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 235000014103 egg white Nutrition 0.000 claims description 2
- 210000000969 egg white Anatomy 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 23
- 210000003491 skin Anatomy 0.000 abstract description 13
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 240000004980 Rheum officinale Species 0.000 abstract description 7
- 230000002757 inflammatory effect Effects 0.000 abstract description 7
- 238000009395 breeding Methods 0.000 abstract description 5
- 230000001488 breeding effect Effects 0.000 abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 244000052616 bacterial pathogen Species 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 238000013329 compounding Methods 0.000 abstract description 3
- 210000000434 stratum corneum Anatomy 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 206010015150 Erythema Diseases 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 231100000321 erythema Toxicity 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 6
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 235000008081 Rheum officinale Nutrition 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 4
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 206010040914 Skin reaction Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229960002504 capsaicin Drugs 0.000 description 3
- 235000017663 capsaicin Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 2
- 240000007926 Ocimum gratissimum Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 2
- -1 anthraquinone compounds Chemical class 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000732800 Cymbidium Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 235000011205 Ocimum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000005770 birds nest Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- NNBFNNNWANBMTI-UHFFFAOYSA-M brilliant green Chemical group OS([O-])(=O)=O.C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 NNBFNNNWANBMTI-UHFFFAOYSA-M 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000001206 effect on leukocytes Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000005765 wild carrot Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an antibacterial and anti-inflammatory plant extract composition and application thereof. According to the invention, the plant extract composition with low addition and strong antibacterial and anti-inflammatory effects is finally obtained by taking the compounding ratio of basil, chlorogenic acid and medicinal rhubarb as an entry point to carry out relevant tests on the antibacterial activity and the addition of the composition. Wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is (1-3) to (0.05-0.2) to (1-3). The composition can effectively inhibit the breeding of skin pathogenic bacteria, and can reduce inflammatory reaction by reducing active oxygen free radicals, eliminating inflammatory factors, improving stratum corneum water loss and the like.
Description
Technical Field
The invention belongs to the field of cosmetics, and relates to preparation and application of an antibacterial and anti-inflammatory plant extract composition.
Background
Due to the influence of the unapproved life style, the continuous change of living environment, the age, the psychological pressure, the environmental pollution, the change of four seasons, the abuse of chemicals and the like, the skin and the mucous membrane of the skin bring a plurality of damages, and the incidence rate of skin diseases shows a continuously rising trend. Modern medical research shows that dysbacteriosis and pathogenic bacteria breeding of a human body can cause endocrine dysfunction, sebum exuberance usually occurs on skin in reaction, and meanwhile, inflammation, acne redness, pimple on the top and the like are caused.
Ocimum basilicum (Ocimum basilicum) is a plant belonging to the genus Ocimum of the order Labiatae, and is called lavender, bird's-nest, cymbidium and West-cowherb, and is a medicinal and edible aromatic plant. The taste is similar to fennel, the whole plant is small and exquisite, the leaf color is emerald green, the flower color is bright, and the fragrance is diffused all around. Basil is one of the main aromatic oil plants, and the volatile oil mainly exists in stems, leaves and flower ears and generally contains 0.1-0.12% of oil. The whole basil herb can be used as a medicine, has warm and pungent properties, has various efficacies of dispelling wind and promoting qi circulation, activating blood circulation, eliminating dampness, promoting digestion, detoxifying and the like, and has nineteen percent of sterilization rate of pure basil essential oil.
Chlorogenic acid (Chlorogenic acid) is an ester formed by caffeic acid and quinic acid, is present in common Chinese herbal medicines such as oriental wormwood, honeysuckle and the like, has a strong broad-spectrum antibacterial effect, and the research on the biological activity of Chlorogenic acid by modern science is deeply carried out in a plurality of fields such as food, health care, medicine, daily chemical industry and the like. Chlorogenic acid is an important bioactive substance, and has antibacterial, antiviral, leukocyte increasing, liver protecting, gallbladder promoting, antitumor, blood pressure lowering, blood lipid reducing, free radical scavenging, and central nervous system exciting effects.
The radix et rhizoma Rhei is dry root and rhizome of Rheum palmatum L, Rheum officinale Baill, Rheum officinale Kitag et al, Rheum tanguticum Maxim. ex Balf. The main functional indications are as follows: purging heat-toxin, breaking stagnation and removing blood stasis. The anthraquinone compounds include emodin, physcion, aloe-emodin, rhein, chrysophanol, etc. The rhubarb has wide antibacterial spectrum and has an inhibiting effect on a plurality of gram-positive bacteria and gram-negative bacteria such as staphylococcus aureus, hemolytic streptococcus, typhoid bacillus, dysentery bacillus, helicobacter pylori and the like; has inhibitory effect on various fungi, influenza virus, hepatitis virus and human immunodeficiency virus.
At present, the application of basil, chlorogenic acid and rhubarb is mainly concentrated in the fields of medicines and food health products, and the application of the basil, the chlorogenic acid and the rhubarb in the field of cosmetics is not much. Singh S finds that the basil volatile oil has obvious inhibition effect on plantar swelling caused by rat carrageenan and edema caused by arachidonic acid and leukotriene, meanwhile, basil (whole plant) extract can reduce ear swelling degree of the rat, and has inhibition effect on leukocyte migration in a rat ballooning model caused by the carrageenan, so that NO and MDA contents in serum are reduced, and SOD activity is enhanced; in recent years, a new antibacterial mechanism of chlorogenic acid has been reported to play a role by reducing the hardness of bacterial cell walls, slowing the migration of bacteria, affecting the stability of bacterial cell membranes and inducing the generation of Reactive Oxygen Species (ROS); researches of Agarwal SK and the like show that the effective components in rhubarb, such as rhein, aloe-emodin, chrysophanol and physcion, have antibacterial effects on cryptococcus neoformans, Leptophyceae and Epsilon, Candida albicans and Aspergillus fumigatus. The rhein, emodin and aloe-emodin in the antibacterial effective components have the most obvious effect.
When the epidermal flora of a human body is disordered, the breeding of pathogenic bacteria can cause inflammatory reaction of the skin, and meanwhile, the generated inflammatory factors can stimulate the skin in turn, so that the increase of active oxygen free radicals is caused, more damage is generated, and the phenomena of acne redness, epidermal water loss and the like occur. Therefore, the invention reduces the risk of skin infection by regulating the biological activity of epidermal flora and inhibiting the breeding of harmful bacteria, and reduces inflammatory reaction by reducing active oxygen free radicals, eliminating inflammatory factors, improving stratum corneum water loss and the like.
The existing research almost rarely mentions the application of the compounding of basil, chlorogenic acid and medicinal rhubarb in the antibacterial activity of the field of cosmetics.
Disclosure of Invention
The invention aims to provide a bacteriostatic anti-inflammatory plant extract composition and application thereof, and solves the problems in the prior art. According to the invention, the plant extract composition with low addition and strong antibacterial and anti-inflammatory effects is finally obtained by taking the compounding ratio of basil, chlorogenic acid and medicinal rhubarb as an entry point to carry out relevant tests on the antibacterial activity and the addition of the composition.
In view of the problems existing in the technical background, the invention aims to provide a preparation method of an anti-inflammatory and bacteriostatic plant extract composition, which comprises the following steps:
1) pulverizing radix et rhizoma Rhei raw material, extracting with deionized water and cellulase, and filtering to obtain first primary filtrate;
2) cutting fresh basil into segments, and extracting with ethanol to obtain a second primary filtrate;
3) mixing the first primary filtrate and the second primary filtrate, concentrating, diluting with water, extracting with organic phase, mixing the organic phases, and concentrating to obtain fluid extract;
4) dissolving the fluid extract with ethanol, adding chlorogenic acid powder for dissolving, concentrating to obtain concentrated solution, and ultrafiltering to obtain the plant extract composition with antiinflammatory and antibacterial effects;
wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is (1-3) to (0.05-0.2) to (1-3).
Preferably, the preparation method comprises the following steps:
1) pulverizing radix et rhizoma Rhei; adding deionized water for extraction, wherein the mass ratio of the rhubarb raw material to the deionized water is 1:20-1:50, and soaking for 1-3 hours; adding cellulase in a water bath at the temperature of 40-50 ℃, wherein the total mass of the added cellulase is 10-20% of the mass of the rhubarb raw material, stirring for 20 minutes, heating to 40-60 ℃, performing microwave treatment for 5-15 minutes, performing ultrasonic water bath reflux extraction for 1-3 hours, cooling to 20-30 ℃, and filtering by using 100-mesh gauze of 200 meshes to obtain a first primary filtrate;
2) cutting fresh basil into 1-2cm sections according to mass ratio, soaking in 3-5 times of 95% ethanol solution for 1h, performing ultrasonic oscillation extraction at low temperature, filtering, and mixing filtrates to obtain second primary filtrate;
3) mixing the first primary filtrate and the second primary filtrate, concentrating under reduced pressure, adding distilled water with 1 volume of the concentrated solution, and sequentially extracting with petroleum ether, chloroform and ethyl acetate; repeating for 2-3 times until the extractive solution is colorless, mixing ethyl acetate layers, and concentrating under reduced pressure to obtain fluid extract;
4) dissolving the extract with 1-3 times volume of ethanol, adding chlorogenic acid powder according to mass ratio, and stirring to dissolve completely; filtering, adding clarifier, standing, centrifuging for 30-60 min, and filtering with microfiltration membrane to obtain filtrate. Concentrating under reduced pressure to recover ethanol to obtain concentrated solution; filtering with ultrafiltration membrane to obtain the plant extract composition with antiinflammatory and antibacterial effects;
wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is (1-3) to (0.05-0.2) to (1-3).
More preferably, the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is 1:0.2:2 or 1:0.1: 3.
Further preferably, the clarifying agent in the step 4) is one or more of a natural clarifying agent, chitosan, a fruit juice clarifying agent, gelatin and egg white.
Further preferably, the pore diameter of the microfiltration membrane in the step 4) is 0.1-1.0 μm; the pore diameter of the ultrafiltration membrane is 0.01-0.05 μm.
The invention also provides an anti-inflammatory and bacteriostatic plant extract composition, which is prepared by the preparation method;
wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is 1:0.2:2 or 1:0.1: 3.
In certain more specific embodiments, the preparation method is specifically:
(1) crushing a large xanthogen material according to a mass ratio;
(2) adding deionized water for extraction, wherein the mass ratio of the raw materials to the deionized water is 1:20, and soaking for 2 hours. Water bath, adding cellulase when the temperature is 48 ℃, stirring for 20 minutes, heating to 54 ℃, performing microwave treatment for 10 minutes, and performing ultrasonic water bath reflux extraction for 3 hours, wherein the total mass of the added cellulase accounts for 10 percent of the total mass of the raw materials;
(3) cooling the extracting solution obtained in the step (2) to room temperature, and filtering with 200-mesh gauze to obtain primary filtrate 1;
(4) cutting fresh basil into 1-2cm sections according to mass ratio, soaking in 3 times of 95% ethanol solution for 1h, extracting at low temperature by ultrasonic oscillation, filtering, and mixing filtrates to obtain primary filtrate 2;
(5) mixing the filtrates of steps (3) and (4), and concentrating under reduced pressure in a rotary evaporator at 55 deg.C to obtain fluid extract; dissolving the extract with 1 time of distilled water, sequentially extracting with petroleum ether, chloroform and ethyl acetate at a volume ratio of 1: 1; shaking for 3 hr, separating organic layer, extracting for 3 times until colorless, mixing ethyl acetate layers, concentrating under reduced pressure in a rotary evaporator, recovering ethyl acetate at 35 deg.C to obtain fluid extract;
(6) dissolving the extract with 3 times of ethanol, adding chlorogenic acid powder according to the mass ratio, stirring to fully dissolve, adding a clarifying agent, standing, centrifuging for 60 minutes, and filtering with a microfiltration membrane to obtain a filtrate. Filtering, concentrating under reduced pressure, and recovering ethanol to obtain concentrated solution.
(7) Characterized in that the rotating speed in the step (5) is 8000 rpm;
(8) and (4) filtering the solution obtained in the step (6) by using an ultrafiltration membrane, and collecting filtrate to obtain the plant extract composition with the effects of resisting inflammation and inhibiting bacteria.
The invention also provides an application of the composition in preparing cosmetics with anti-inflammatory and bacteriostatic effects.
The invention also provides a cosmetic comprising the composition and cosmetically acceptable adjuvants.
Preferably, the composition accounts for 0.5-5% of the cosmetic by mass.
Preferably, the cosmetic is a water, an emulsion, a spray, a cream, a gel or a mask.
The application has the following beneficial effects:
1) can effectively inhibit the breeding of skin pathogenic bacteria, and has no influence on normal flora of skin epidermis.
2) Can reduce inflammatory reaction by reducing active oxygen free radicals, eliminating inflammatory factor, improving horny layer water loss, etc.
3) Compared with the conventional bacteriostatic composition, the bacteriostatic composition disclosed by the invention uses natural products as raw materials, and is safer and non-irritant.
Drawings
FIG. 1 is a graph of the effect of different compositions on IL1- α secretion;
FIG. 2 is a graph of the effect of different compositions on IL-6 secretion;
FIG. 3 is a graph of the effect of different compositions on transdermal water loss;
figure 4 is a graph of the effect of different compositions on erythema.
Detailed Description
Embodiments of the present application will be described in detail by examples, so that how to apply technical means to solve technical problems and achieve technical effects of the present application can be fully understood and implemented.
The raw materials and equipment used in the present application are all common raw materials and equipment in the field, and are all from commercially available products, unless otherwise specified. The methods used in this application are conventional in the art unless otherwise indicated.
There are many other possible embodiments of the present invention, which are not listed here, and the embodiments claimed in the claims of the present invention can be implemented.
Example 1 preparation of a plant extract composition effective against inflammation and bacteria
In the following examples and comparative examples of the present invention, the plant extract composition effective in anti-inflammatory and bacteriostatic effects was prepared by the following process.
(1) Crushing a large xanthogen material according to a mass ratio;
(2) adding deionized water for extraction, wherein the mass ratio of the raw materials to the deionized water is 1:20-1:50, and soaking for 1-3 hours. Adding cellulase in water bath at 40-50 deg.C, stirring for 20 min, heating to 40-60 deg.C, performing microwave treatment for 5-15 min, and performing ultrasonic water bath reflux extraction for 1-3 hr;
(3) cooling the extracting solution obtained in the step (2) to 20-30 ℃, and filtering with 100-200-mesh gauze to obtain primary filtrate 1;
(4) cutting fresh basil into 1-2cm sections according to mass ratio, soaking in 3-5 times of 95% ethanol solution for 1h, performing ultrasonic oscillation extraction at low temperature, filtering, and mixing filtrates to obtain primary filtrate 2;
(5) mixing the filtrates of steps (3) and (4), and concentrating under reduced pressure in a rotary evaporator at 50-60 deg.C to obtain fluid extract; dissolving the extract with 1 time of distilled water, sequentially extracting with petroleum ether, chloroform and ethyl acetate at a volume ratio of 1: 1; shaking for 2-4 hr, separating organic layer, extracting for 2-3 times until colorless, mixing ethyl acetate layers, concentrating under reduced pressure in a rotary evaporator, recovering ethyl acetate at 35-50 deg.C to obtain fluid extract;
(6) dissolving the extract with 1-3 times of ethanol, adding clarifier, standing, centrifuging for 30-60 min, filtering with microfiltration membrane to obtain filtrate, and reflux-extracting with 1-3 times of solution for 3-5 hr. Adding chlorogenic acid powder according to the mass ratio, and stirring until the chlorogenic acid powder is fully dissolved. Filtering, concentrating under reduced pressure, and recovering ethanol to obtain concentrated solution.
(7) Characterized in that the rotating speed in the step (5) is 5000-10000 rpm;
(8) and (4) filtering the solution obtained in the step (6) by using an ultrafiltration membrane, and collecting filtrate to obtain the plant extract composition with the effects of resisting inflammation and inhibiting bacteria.
Example 2 evaluation of antioxidant efficacy of composition combinations of different proportions
(1) Crushing a large xanthogen material according to a mass ratio;
(2) adding deionized water for extraction, wherein the mass ratio of the raw materials to the deionized water is 1:20, and soaking for 2 hours. Water bath, adding cellulase when the temperature is 48 ℃, stirring for 20 minutes, heating to 54 ℃, performing microwave treatment for 10 minutes, and performing ultrasonic water bath reflux extraction for 3 hours, wherein the total mass of the added cellulase accounts for 10 percent of the total mass of the raw materials;
(3) cooling the extracting solution obtained in the step (2) to room temperature, and filtering with 200-mesh gauze to obtain primary filtrate 1;
(4) cutting fresh basil into 1-2cm sections according to mass ratio, soaking in 3 times of 95% ethanol solution for 1h, extracting at low temperature by ultrasonic oscillation, filtering, and mixing filtrates to obtain primary filtrate 2;
(5) mixing the filtrates of steps (3) and (4), and concentrating under reduced pressure in a rotary evaporator at 55 deg.C to obtain fluid extract; dissolving the extract with 1 time of distilled water, sequentially extracting with petroleum ether, chloroform and ethyl acetate at a volume ratio of 1: 1; shaking for 3 hr, separating organic layer, extracting for 3 times until colorless, mixing ethyl acetate layers, concentrating under reduced pressure in a rotary evaporator, recovering ethyl acetate at 35 deg.C to obtain fluid extract;
(6) dissolving the extract with 3 times of ethanol, adding chlorogenic acid powder according to the mass ratio, stirring to fully dissolve, adding a clarifying agent, standing, centrifuging for 60 minutes, and filtering with a microfiltration membrane to obtain a filtrate. Filtering, concentrating under reduced pressure, and recovering ethanol to obtain concentrated solution.
(7) Characterized in that the rotating speed in the step (5) is 8000 rpm;
(8) and (4) filtering the solution obtained in the step (6) by using an ultrafiltration membrane, and collecting filtrate to obtain the plant extract composition with the effects of resisting inflammation and inhibiting bacteria.
The three plant extracts were compounded according to the following ratio in table 1 to obtain compositions 1-15, comparative examples 1-3.
TABLE 1
In the composition and the comparative example of the invention, the method for testing the bacteriostasis and repair effect of the bacteriostatic and anti-inflammatory plant extract composition and the results are as follows:
detection of bacteriostatic effects
Selecting strains: staphylococcus aureus, pseudomonas aeruginosa, propionibacterium acnes; the preparation of the bacterial liquid selects pseudomonas aeruginosa, staphylococcus aureus and propionibacterium acnes as listed strains. Preparation: it was diluted to about 1.0x10 with sterile physiological saline5cfu/ml～1.0x106cfu/ml ofAnd (4) bacterial suspension. The prepared bacterial suspension can be used within 2h, or can be stored at 2-8 ℃ for no more than 24 h.
And (3) detecting the antibacterial effect: the plant composition obtained in step (8) of example 2 was taken, and 20. mu.L of the actual plant composition was dropped onto each of sterile dried filter paper sheets. Test bacterium inoculation: taking 1mL of each test bacterial suspension, and uniformly smearing the test bacterial suspension on the surface of a nutrient agar culture medium; the bacteriostatic test samples are attached, one bacterial staining flat plate is attached to each test, 4 filter paper sheets are attached to each dish, 3 filter paper sheets are test sample sheets, and 1 filter paper sheet is blank. A sample piece is attached to the surface of the flat plate by using a sterile forceps, the flat plate is placed in a constant temperature incubator at 36 +/-1 ℃, the result is observed after the flat plate is cultured for 18 hours, and the diameter of the antibacterial ring is measured by using a vernier caliper. The results are the average of 3 measurements.
The experimental results are as follows: results table 2 below, comparing compositions 1-15 with comparative examples 1-3, it was found that:
1) the bacteriostatic activity of the compounded and combined 3 raw materials is superior to that of a single plant;
2) the antibacterial activities corresponding to different proportions of the plant compound combination are different, preferably, the antibacterial activities are as follows: chlorogenic acid: rheum officinale (1-3): (0.05-0.2): 1-3), more preferably basil: chlorogenic acid: rhubarb is 1:0.2:2 or 1:0.1: 3.
TABLE 2
The test results show that the compositions in the test examples 1 to 15 have good bacteriostatic effects compared with the blank group, but the compositions have different proportions under the same condition and influence the bacteriostatic intensity of various bacteria, wherein the bacteriostatic effects of the compositions 6, 8 and 10 are relatively good.
Example 3 detection of cellular inflammation
(1) MTT cytotoxicity assay
In 96well Multi plate (corning)According to 1X104cells/well were seeded at a density of 100. mu.L each in DMEM medium containing 10% bovine serum and keratinocytes (HaCaT), and 24 hours later in culture were replaced with serum-free medium. The compositions 6, 8 and 10 of the above examples were added to serum-free medium, respectively, and the mixture was cultured for 24 hours after treatment. Thereafter, the medium was removed, treated with 20. mu.L of MTT solution, and allowed to react at 37 ℃ for 2 hours. 200 μ L of isopropanol was added to the cells from which the MTT solution was removed, gently shaken for 30min to completely dissolve the crystalline formazan, absorbance was measured at 570nm, and cell viability was calculated according to the following formula.
The control group was tested without the addition of sample. The cytotoxicity-related results are shown in table 3 below.
TABLE 3
(2) Inflammatory factor detection
IL 1-alpha and IL-6 are cell inflammatory factors and are detected by an ELISA method. HaCat cells without any treatment were used as a blank group, and HaCat cells induced by Lipopolysaccharide (LPS) were used as a model group. After stimulation of HaCat cells with 1. mu.g/ml LPS, 1% of the composition 6, 8, 10 was added to 12-well cell plates at 100. mu.l per well, at 37 ℃ in 5% CO2Incubate at constant temperature for 72h, 3 replicates per experimental group. And collecting cell culture supernatant, carrying out anti-inflammatory efficacy evaluation by an ELISA detection kit, and averaging results. The test is as follows, taking the content detected by blank group as the reference, namely 100%.
Specific results are shown in FIGS. 1 and 2, where FIG. 1 shows the effect of different compositions on IL1- α secretion; FIG. 2 is a graph showing the effect of different compositions on IL-6 secretion. The results show that the compositions 6, 8 and 10 can well inhibit the generation of IL 1-alpha and IL-6 inflammatory factors after being stimulated by LPS, have obvious anti-inflammatory effect and have the best effect of the composition 10.
Example 4.
In a specific embodiment, the invention provides a formula process of a mask muscle base solution capable of effectively resisting inflammation and inhibiting bacteria, and the specific formula is as follows:
TABLE 4
The extract of claim was added and compositions 6, 8, 10 were added to the mask muscle base formulation of table 5 below, using formulations commonly used in the art, at an add-on level of 1%, to make mask muscle base examples 1-3.
TABLE 5
| Composition 6 | Composition 8 | |
| Sample 1 | |
Sample 3 |
1. Safety test (human skin patch test)
Selecting 15 healthy subjects with no allergic history of skin diseases between the ages of 20 and 50, and performing a spot pasting method: selecting a qualified spot tester, dropping about 15 mu L of samples 1-3 into the spot tester in a closed spot test mode, externally sticking a special adhesive tape on the back of a test subject, sticking 20 spot testers on each test subject, respectively sticking muscle base fluid samples of the samples 1-3, removing the test substances after 24 hours, observing skin reactions after 0.5, 6, 12, 24 and 48 hours after removal, and recording the results according to the skin reaction grade standard in skin care product sanitation standard.
And (3) test results: the results of the human skin patch test show that all the subjects pass the patch test, and the skin reaction is observed in 0.5, 6, 12, 24 and 48 hours, wherein 0 case has adverse reactions such as skin erythema, pimple and blister, which indicates that the product of the invention is safe and non-irritant.
2. Skin Water loss and erythema repair test
(1) The number of tested persons: a total of 45 persons; divided into 5 groups of 9 people each.
(2) The tested part: the skin of the forearm flexor side of the tested person;
(3) sterilizing the part to be tested with 70% ethanol, and measuring skin color ERYTHEMA value (ERYTHEMA) and TEWL value after the ethanol is completely evaporated; selecting 1x 1cm on weak skin of forearm of human subject2The areas of (a) are control (blank), model (0.075% capsaicin challenge), and the rest are test groups. Wherein the test groups were protected with the preferred compositions 6, 8, 10(20 μ L, 10mg/mL), stimulated with 0.075% capsaicin, and then skin color erythema and TEWL values were measured after 30min to evaluate the repair status.
Specific results are shown in fig. 3 and 4, fig. 3 being the effect of different compositions on transdermal water loss
The experimental results are as follows: the respective plant extract compositions are effective in relieving the rise of percutaneous water loss (TEWL) and the increase of ERYTHEMA (ERYTHEMA) due to capsaicin stimulation, while the comparative examples have limited relieving effects on TEWL and ERYTHEMA.
The details not described in the specification of the present application belong to the common general knowledge of those skilled in the art.
In the following description and in the claims, the terms "include" and "comprise" are used in an open-ended fashion, and thus should be interpreted to mean "include, but not limited to. "substantially" means within an acceptable error range, and a person skilled in the art can solve the technical problem within a certain error range to substantially achieve the technical effect.
It is also noted that the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a good or system that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such good or system. Without further limitation, an element defined by the phrase "comprising an … …" does not exclude the presence of other like elements in a commodity or system that includes the element.
The foregoing description shows and describes several preferred embodiments of the present application, but as aforementioned, it is to be understood that the application is not limited to the forms disclosed herein, but is not to be construed as excluding other embodiments and is capable of use in various other combinations, modifications, and environments and is capable of changes within the scope of the inventive concept as expressed herein, commensurate with the above teachings, or the skill or knowledge of the relevant art. And that modifications and variations may be effected by those skilled in the art without departing from the spirit and scope of the application, which is to be protected by the claims appended hereto.
Claims (10)
1. The preparation method of the plant extract composition with anti-inflammatory and bacteriostatic effects is characterized by comprising the following steps of:
1) pulverizing radix et rhizoma Rhei raw material, extracting with deionized water and cellulase, and filtering to obtain first primary filtrate;
2) cutting fresh basil into segments, and extracting with ethanol to obtain a second primary filtrate;
3) mixing the first primary filtrate and the second primary filtrate, concentrating, diluting with water, extracting with organic phase, mixing the organic phases, and concentrating to obtain fluid extract;
4) dissolving the fluid extract with ethanol, adding chlorogenic acid powder for dissolving, concentrating to obtain concentrated solution, and ultrafiltering to obtain the plant extract composition with antiinflammatory and antibacterial effects;
wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is (1-3) to (0.05-0.2) to (1-3).
2. The method of claim 1, comprising the steps of: 1) pulverizing radix et rhizoma Rhei; adding deionized water for extraction, wherein the mass ratio of the rhubarb raw material to the deionized water is 1:20-1:50, and soaking for 1-3 hours; adding cellulase in a water bath at the temperature of 40-50 ℃, wherein the total mass of the added cellulase is 10-20% of the mass of the rhubarb raw material, stirring for 20 minutes, heating to 40-60 ℃, performing microwave treatment for 5-15 minutes, performing ultrasonic water bath reflux extraction for 1-3 hours, cooling to 20-30 ℃, and filtering by using 100-mesh gauze of 200 meshes to obtain a first primary filtrate;
2) cutting fresh basil into 1-2cm sections according to mass ratio, soaking in 3-5 times of 95% ethanol solution for 1h, performing ultrasonic oscillation extraction at low temperature, filtering, and mixing filtrates to obtain second primary filtrate;
3) mixing the first primary filtrate and the second primary filtrate, concentrating under reduced pressure, adding distilled water with 1 volume of the concentrated solution, and sequentially extracting with petroleum ether, chloroform and ethyl acetate; repeating for 2-3 times until the extractive solution is colorless, mixing ethyl acetate layers, and concentrating under reduced pressure to obtain fluid extract;
4) dissolving the extract with 1-3 times volume of ethanol, adding chlorogenic acid powder according to mass ratio, stirring to dissolve completely, adding clarifier, standing, centrifuging for 30-60 min, and filtering with microfiltration membrane to obtain filtrate; filtering, concentrating under reduced pressure, and recovering ethanol to obtain concentrated solution; filtering with ultrafiltration membrane to obtain the plant extract composition with antiinflammatory and antibacterial effects;
wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is (1-3) to (0.05-0.2) to (1-3).
3. The method of claim 2, wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is 1:0.2:2 or 1:0.1: 3.
4. The preparation method of claim 3, wherein the clarifying agent in the step 4) is one or more of natural clarifying agent, chitosan, juice clarifying agent, gelatin and egg white.
5. The method according to claim 3, wherein the pore size of the microfiltration membrane in the step 4) is 0.1 to 1.0 μm; the pore diameter of the ultrafiltration membrane is 0.01-0.05 μm.
6. An anti-inflammatory bacteriostatic plant extract composition prepared by the preparation method of any one of claims 1 to 5;
wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is 1:0.2:2 or 1:0.1: 3.
7. Use of a composition according to claim 6 for the preparation of a cosmetic product with anti-inflammatory and bacteriostatic effects.
8. A cosmetic comprising the composition of claim 6 and cosmetically acceptable adjuvants.
9. The cosmetic of claim 8, wherein the composition is present in an amount of 0.5 to 5% by weight of the cosmetic.
10. The cosmetic of claim 8, wherein the cosmetic is a lotion, emulsion, spray, cream, gel, or mask.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110771103.8A CN113712858B (en) | 2021-07-07 | 2021-07-07 | Preparation and application of antibacterial and anti-inflammatory plant extract composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110771103.8A CN113712858B (en) | 2021-07-07 | 2021-07-07 | Preparation and application of antibacterial and anti-inflammatory plant extract composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113712858A true CN113712858A (en) | 2021-11-30 |
| CN113712858B CN113712858B (en) | 2024-02-13 |
Family
ID=78673119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110771103.8A Active CN113712858B (en) | 2021-07-07 | 2021-07-07 | Preparation and application of antibacterial and anti-inflammatory plant extract composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113712858B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961376A (en) * | 2010-07-23 | 2011-02-02 | 新疆医科大学 | Method for refining sweet basil herb extract |
| CN108308203A (en) * | 2018-01-31 | 2018-07-24 | 南京紫源康医药科技有限公司 | A kind of preparation method of Chinese medicinal compound extract, extract and bacteria inhibiting composition |
-
2021
- 2021-07-07 CN CN202110771103.8A patent/CN113712858B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961376A (en) * | 2010-07-23 | 2011-02-02 | 新疆医科大学 | Method for refining sweet basil herb extract |
| CN108308203A (en) * | 2018-01-31 | 2018-07-24 | 南京紫源康医药科技有限公司 | A kind of preparation method of Chinese medicinal compound extract, extract and bacteria inhibiting composition |
Non-Patent Citations (1)
| Title |
|---|
| 周秋丽等: "现代中药基础研究与临床", vol. 1, 天津科技翻译出版公司, pages: 107 - 21 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113712858B (en) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101452770B1 (en) | Cosmetic composition comprising lactobacillus fermented solution having anti-oxidation, whitening and anti-wrinkle effect | |
| CN111973515B (en) | Bacteriostatic restoration plant extraction composition, preparation method and application thereof | |
| KR102232572B1 (en) | Manufacturing method for cosmetic pomposition comprising centella asiatica extract | |
| KR101002012B1 (en) | Cosmetic composition containing the extract of cornus kousa, rosa multiflora, torreya nucifera, musa basjoo and chloranthus glaber(thunb.) makino | |
| CN116492385B (en) | Compound essential oil for repairing skin and pharmaceutical composition containing compound essential oil | |
| Tofiq et al. | Wound healing activities of Moringa oleifera leaves extract cultivated in Kurdistan region-Iraq. | |
| KR101033921B1 (en) | Composition for reducing irritation and inflammation in skin | |
| KR20110130184A (en) | An extract of cudrania tricuspidata and a cosmetic composition containing the extract with anti-acne effect | |
| KR20160050527A (en) | Composition of cosmetics for anti-wrinkle containing Ulva pertusa Kjellman extracts | |
| CN113712858B (en) | Preparation and application of antibacterial and anti-inflammatory plant extract composition | |
| KR101427462B1 (en) | Composite Natural Antiseptics From Forsythia suspensa Vahl, Leonurus sibiricus L., Crataegi fructus and Akebia quinata Decaisne, Cosmetic Compositions Containing Them | |
| CN115414308A (en) | Acne removing composition as well as preparation method and application thereof | |
| KR101587446B1 (en) | Cosmetic composition with the IL-S extract by subcritical water extraction with anti-bacterial, moisturizing, itching improvement, increased ceramide, anti-inflammatory effect | |
| KR101574248B1 (en) | Cosmetic composition comprising Reynoutria sachalinensis extracts for skin anti-wrinkle effect | |
| KR20210096436A (en) | Shampoo Composition and manufacturing mehtod thereof | |
| KR20210065591A (en) | Functional cosmetic composition comprising buah merah fruit oil and clove flower extract as active ingredients | |
| EP2841079B1 (en) | New compositions for the treatment of chronic ulcers | |
| CN115251093B (en) | Disinfectant composition containing aromatic Chinese medicinal essential oil and guarana extract and preparation method thereof | |
| KR102216902B1 (en) | Skin care | |
| KR102446610B1 (en) | Cleansing composition having increased scopolin, scopoletin and ginsenosides and its use | |
| Indrawati et al. | Potential of Purple Sweet Potato (Ipomoea batatas var. Ayamurasaki) Skin Extract Cream Preparation as an Antibacterial Against the Growth Activity of Propionibacterium acnes | |
| KR20240015492A (en) | Cosmetic composition for skin improvement that shows antibacterial activity and antibacterial effect using a mixed extract of Distromium decumbens, Rosa rugosaThunb., Persicaria hydropiper L. | |
| Dwiyanti et al. | Traditional Mask Made From Mangosteen Peel Extract (Garcinia Mangostana L) As Pimply Skinface Treatment | |
| KR20030016547A (en) | Cosmetic composition for cutis elastica or skin-moisture containing Trichosanthes kirilowii and/or Origanum Majorana | |
| KR20230087208A (en) | Korean medicinal green tea callus ferment filtrate for improving atopic dermatitis and cosmetic composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |